Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Saudi Arabia

- PMLiVE

Advent tops Cinven offer for Stada as third suitor looms

Values the OTC and generics specialist at €3.6bn, with offer open until 27 February

AstraZeneca AZ

AZ agrees to $320m deal for Zoladex

TerSera Therapeutics acquires rights to oncology drug in US and Canada

- PMLiVE

Marathon pauses Emflaza launch amid pricing furore

US Senator Bernie Sanders calls Duchenne muscular dystrophy drug’s pricing “unconscionable”

- PMLiVE

Stada confirms Cinven as one of two takeover bidders

Private equity group offers €3.6bn for the generics and over-the-counter medicines manufacturer

- PMLiVE

FDA approves first steroid for Duchenne muscular dystrophy

Marathon Pharma’s Emflaza is first approved to treat all genetic forms of the condition

- PMLiVE

Amgen’s chronic kidney disease drug Parsabiv cleared in US

Sensipar follow-up is the first therapy to be approved for treatment of sHPT in 12 years

- PMLiVE

Biotech leaders slam Trump over immigration order

Former Teva CEO Jeremy Levin heads open letter expressing “deep concern and opposition”

- PMLiVE

Cello Health expands with Defined Health acquisition

Builds US presence with biotech-focused strategy specialist

- PMLiVE

Heart research campaign urges chocolate detox for workers

British Heart Foundation hopes to inspire officer workers to abstain in March

- PMLiVE

Trump talks pricing and manufacturing with pharma

Heads of Celgene, Lilly, Merck & Co, Novartis and trade body PhRMA met at the White House

- PMLiVE

Novo Nordisk invests £115m in Oxford diabetes unit

But Danish pharma company admitted Brexit had made it a harder decision

- PMLiVE

J&J pondering future of diabetes device assets

Three diabetes care subsidiaries under review as firm forecasts measured 2017 sales

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links